An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 8, 2023

Primary Completion Date

May 2, 2033

Study Completion Date

May 2, 2033

Conditions
Alpha1-Antitrypsin Deficiency
Interventions
DRUG

Fazirsiran Injection

Fazirsiran will be injected subcutaneously.

Trial Locations (10)

52074

Universitätsklinikum der RWTH Aachen, Aachen

94063

Stanford Medicine Outpatient Center, Redwood City

92037-1337

UCSD Altman Clinical and Translational Research Institute, La Jolla

32610-3010

UF Clinical and Translational Science Institute, Gainesville

52242-1009

University Of Iowa Hospitals And Clinics, Iowa City

29425-8900

Medical University of South Carolina - Hollings Cancer Center - PPDS, Charleston

A-1090

Medizinische Universitat Wien (Medical University of Vienna), Vienna

9000-168

Hospital Nélio Mendonça, Funchal

CB2 0QQ

Addenbrooke's Hospital, Cambridge

EH16 4SA

Royal Infirmary of Edinburgh - PPDS, Edinburgh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY